<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487253</url>
  </required_header>
  <id_info>
    <org_study_id>50100119</org_study_id>
    <nct_id>NCT00487253</nct_id>
  </id_info>
  <brief_title>Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia</brief_title>
  <official_title>Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Internacional de Entrenamiento e Investigaciones Médicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Dermatología Centro dermatológico Federico Lleras Acosta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Internacional de Entrenamiento e Investigaciones Médicas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, open label clinical trial is to determine if oral miltefosine
      is a safe and effective alternative, compared with parenteral meglumine antimoniate for the
      treatment of pediatric Cutaneous caused by L. Viannia species in Colombia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be the proportion of &quot;Therapeutic Failures&quot; diagnosed during the final (week 26) visit or before, according to defined clinical criteria.</measure>
    <time_frame>26 weeks (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of clinical or laboratory toxicity during the treatment period.</measure>
    <time_frame>During the treatment period (20 or 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &quot;parasitologic&quot; response 26 weeks after the initiation of treatment.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.
presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine</intervention_name>
    <description>Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Miltefosine cap 10mg and 50mg, Impavido® (Zentaris)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate</intervention_name>
    <description>Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Glucantime® of Aventis: Amp of 5ml (83mg/ml).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 to 12 years of age (inclusive)

          -  Parasitologically confirmed CL

          -  Availability to receive supervised treatment for 28 days (i.e., directly observed
             therapy, to ensure the therapy is appropriately administered and received - e.g., the
             miltefosine is &quot;swallowed&quot;)

          -  Availability to return for follow-up visits for at least 6 months after treatment is
             initiated

        Exclusion Criteria:

          -  Weight under 10kg

          -  Previous use of SbV, miltefosine or other antileishmanial therapy

          -  Simultaneous mucosal lesions suggestive of or proven to be mucosal leishmaniasis

          -  If a girl, ability to reproduce (history of menarche)

          -  Relative or absolute contraindications for the use of SbV drugs or miltefosine,
             including history of cardiac, renal or hepatic disease

          -  Patients with pretreatment haemoglobin &lt;10g/dl or blood urea nitrogen (BUN), serum
             creatinine, ALT, AST or amylase values that exceed the upper limit of normal

          -  If living in Malaria endemic areas (eg. Tumaco) only: A positive malaria thick smear
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luisa Consuelo Rubiano, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Internacional de Entrenamiento e Investigaciones Médicas</affiliation>
  </overall_official>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <last_update_submitted>February 13, 2010</last_update_submitted>
  <last_update_submitted_qc>February 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Santiago Nicholls</name_title>
    <organization>Instituto Nacional de Salud</organization>
  </responsible_party>
  <keyword>Cutaneous Leishmaniasis</keyword>
  <keyword>Leishmania Viannia</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Miltefosine</keyword>
  <keyword>Randomized</keyword>
  <keyword>Colombia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Meglumine antimoniate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 2, 2011</submitted>
    <returned>February 23, 2011</returned>
    <submitted>October 13, 2011</submitted>
    <returned>November 18, 2011</returned>
    <submitted>November 18, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 19, 2011</submitted>
    <returned>December 21, 2011</returned>
    <submitted>September 4, 2012</submitted>
    <returned>October 3, 2012</returned>
    <submitted>March 26, 2015</submitted>
    <returned>April 27, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

